Six studies investigated the effect of vortioxetine (LU AA21004), a medication with 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors and 5-HT transporter affinities, on MDD symptoms. Here, HTR3A is linked to major depressive disorder.